Short answer · Medically reviewed summary · Last updated: 2023-07-13
Warm Antibody Hemolytic Anemia (WAHA) is a relatively rare autoimmune disorder characterized by the destruction of red blood cells by autoantibodies at body temperature. It is the most common form of autoimmune hemolytic anemia, accounting for approximately 70-80% of cases. The prevalence of WAHA varies among different populations and regions.
What is the prevalence of Warm Antibody Hemolytic Anemia?
Prevalence of Warm Antibody Hemolytic Anemia: how many people are affected worldwide, differences by sex and region, with sources.
Warm Antibody Hemolytic Anemia (WAHA) is a relatively rare autoimmune disorder characterized by the destruction of red blood cells by autoantibodies at body temperature. It is the most common form of autoimmune hemolytic anemia, accounting for approximately 70-80% of cases.
The prevalence of WAHA varies among different populations and regions. In the United States, it is estimated that WAHA affects around 1-3 individuals per 100,000 population per year. However, the prevalence may be higher in certain groups, such as the elderly and those with underlying autoimmune diseases.
WAHA can occur at any age, but it is more commonly diagnosed in adults, with a peak incidence between 40 and 60 years old. It affects both males and females equally.
Diagnosis of WAHA involves a combination of clinical evaluation, laboratory tests, and identification of autoantibodies targeting red blood cells. Treatment options include corticosteroids, immunosuppressive drugs, and in severe cases, splenectomy or blood transfusions.
While WAHA is not a widely prevalent condition, it can significantly impact the quality of life and overall health of affected individuals. Early diagnosis and appropriate management are crucial in minimizing complications and improving outcomes for patients with this autoimmune disorder.
